GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the third quarter of 2025 and provided a business update highlighting key progress across its vaccine and oncology programs. The company accelerated development of its GEO-MVA mpox/smallpox vaccine in response to the World Health Organization’s reaffirmation of mpox as a global public health emergency, with clade I outbreaks spreading across Africa, Europe, and the United States. Favorable scientific advice from the European Medicines Agency (EMA) supported a streamlined regulatory pathway, positioning GeoVax to become a diversified supplier of MVA vaccines. A new research collaboration with the University of Queensland and UniQuest will evaluate needle-free delivery using Vaxxas’ high-density microarray patch platform, aiming to improve thermostability and dose-sparing, which are critical for pandemic preparedness and global vaccine equity.
In its COVID-19 vaccine program, GeoVax released encouraging interim data from Phase 2 trials of GEO-CM04S1 in immunocompromised populations, including patients with chronic lymphocytic leukemia (CLL) and hematologic cancers. Data presented at the 6th ESCMID Conference on Vaccines and the iwCLL 2025 Workshop showed robust T-cell and cross-variant antibody responses that exceeded those of standard mRNA vaccines, with no serious adverse events. The CLL trial met its immunogenicity endpoint, leading to discontinuation of the comparator mRNA arm. The company plans to launch a next-generation construct incorporating the Omicron KP.2 spike gene in 2026.
GeoVax’s oncology program, Gedeptin, is expanding into new solid tumor indications. Following the KEYNOTE-689 Phase 3 results, GeoVax announced plans for a Phase 2 trial evaluating Gedeptin plus pembrolizumab and fludarabine in first-line resectable head and neck squamous cell carcinoma, with initiation targeted for the second half of 2026. Preclinical studies are also expanding into triple-negative breast and cutaneous cancers in collaboration with Emory University’s Winship Cancer Institute.
Financially, GeoVax reported a net loss of $6.3 million for the third quarter of 2025, compared to $5.8 million in the same period of 2024. Research and development expenses decreased to $5.0 million from $7.4 million, primarily due to the termination of the BARDA/RRPV Project NextGen contract. General and administrative expenses rose to $1.3 million from $1.2 million. Cash and cash equivalents stood at $5.0 million as of September 30, 2025.
GeoVax continues to engage with agencies such as ASPR, BARDA, CEPI, Africa CDC, WHO, and UNICEF, aligning its U.S.-based MVA platform with national priorities for onshoring vaccine manufacturing and pandemic preparedness. The company’s continuous avian cell line manufacturing process supports legislative goals to modernize domestic biomanufacturing.
